Intravenous, non-viral RNAi gene therapy of brain cancer.
about
Epigenetics of Alzheimer's disease and frontotemporal dementiaSmall Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral EffectProgress and problems in the application of focused ultrasound for blood-brain barrier disruption.Present and potential future issues in glioblastoma treatment.Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies.Drug delivery to brain tumours: challenges and progress.Structure and stability of the complex formed by oligonucleotides.Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon.Nanomedicine in GINanotechnology for energy-based cancer therapiesFrom the liver to the brain across the blood-brain barrier.Chaperone proteins and brain tumors: potential targets and possible therapeutics.MicroRNA and brain tumors: a cause and a cure?The therapeutic potential of RNA interference.RNA knockdown as a potential therapeutic strategy in Parkinson's disease.Knocking down transport: applications of RNA interference in the study of drug transport proteins.Silencing neurodegenerative disease: bringing RNA interference to the clinic.RNAi based approaches to the treatment of malignant glioma.RNA interference in pain research.Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies.Targeting potassium channels for increasing delivery of imaging agents and therapeutics to brain tumors.microRNAs: innovative targets for cerebral ischemia and stroke.Delivery of small-interfering RNA (siRNA) to the brain.Strategies for short hairpin RNA delivery in cancer gene therapy.Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.RNA interference therapy for glioblastoma.Delivery of RNAi therapeutics: work in progress.Anticancer effects of chemokine receptor 4(CXCR4) gene silenced by CXCR4-siRNA in nude mice model of ovarian cancer.HA-coated chitosan nanoparticles for CD44-mediated nucleic acid delivery.Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers.Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacyBrain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders.Regulating MHC expression for cellular therapeutics.Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis.Neuroprotective effects of microRNA-210 on hypoxic-ischemic encephalopathy.Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB).Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels.Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice.Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo.
P2860
Q27010153-BFC87939-B6D0-496E-8E80-73695249A2BFQ27478036-4A665F4F-D723-47A8-B761-4D85BB522374Q30487878-2AAD00AE-E570-4FD5-9DD1-FCFB60AA96A6Q31043603-07A5D352-9947-420F-9FB4-2095DDCE8A26Q33996836-DB7C0F98-F0D6-4062-8F07-64074F9C6AA7Q33997439-BE6FA923-A6A9-4724-A2F7-8D92B6EC33C8Q34239895-F81B5756-49BE-4849-B8FB-AF7CFA67F7C5Q34354205-F3ECAD9F-4643-41CD-9630-CB332CDA8833Q34719056-8E2A2626-86DB-4D5B-9B62-D8D580A155FEQ35264028-98080597-374D-40E1-9221-5D640C56EC94Q35778166-2CD66093-EB23-48DC-9098-E68642BB1A5EQ35800492-E0C956DA-A19E-40B9-9894-D594D8295D96Q36065652-98FD565F-656D-4E5F-A702-8C410783F777Q36237868-78CAEA0A-E94D-49A6-BEB1-9B6096FFAB8AQ36305419-CB77ECC7-D140-41E4-A120-A136406743A5Q36360814-180A7023-A0E9-4BC9-BC9B-4A1AF65AA835Q36390831-038EE7CC-EA7C-4BDC-8F45-37B08411D704Q36478665-95578A39-A9C1-401A-9325-07120C2AE34DQ36618289-23FB67CA-E2EF-40BA-BA78-77938CAE4C9CQ36752048-02236CDB-D5C8-48E6-86A3-7DAF845FCFF9Q36881899-6BE8B4EE-7721-4151-ADAA-2888A9001026Q36905867-44570964-47B9-4110-932E-756D29FCA565Q37481282-4502189A-4D9B-4FF5-9FD3-B1030EA9C89BQ37598928-339F82AB-09C8-4DF5-8379-3F29BACDE27BQ37690479-CFC00D65-ECC0-45FB-8F76-441B8B4A0654Q37736499-3A8F76F6-3013-42A8-833D-1E7762E3A95BQ38160246-F68868E5-F811-4ED9-B0F2-532528D57F8CQ38963532-6D7B0C5C-76F1-479C-A8DB-29FC948B4056Q39084265-ED83A80A-AE71-4FA8-B985-8B9278FD72F7Q39520806-EC66408A-D123-4193-A56C-66BDA84B8252Q39595667-8AF1C9C5-CBC6-4756-A53B-1778EB89C0B5Q39738982-CAC3AB9A-E693-4D2F-B88E-45233CBD90CCQ40186054-591DC843-404B-4AD7-97E9-08E83AD2FDB2Q42608288-4478AE6D-BBA3-4E4E-8524-85BE14844D24Q44066855-A1DE4764-5C41-44CA-B2E2-ABB67786F082Q48238485-47146E07-697E-4AED-9148-E9C73E005D3EQ48587261-5F9196E2-9809-4C0A-AF31-E0010D42C4E9Q52581027-DBC0D777-8613-411A-AF05-18788CDEEF4DQ54534471-365B6FC8-4CB8-4E6A-9DBD-415F70914384Q55427986-37330F96-3B60-4711-B9D0-5D47233ECF4A
P2860
Intravenous, non-viral RNAi gene therapy of brain cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Intravenous, non-viral RNAi gene therapy of brain cancer.
@ast
Intravenous, non-viral RNAi gene therapy of brain cancer.
@en
type
label
Intravenous, non-viral RNAi gene therapy of brain cancer.
@ast
Intravenous, non-viral RNAi gene therapy of brain cancer.
@en
prefLabel
Intravenous, non-viral RNAi gene therapy of brain cancer.
@ast
Intravenous, non-viral RNAi gene therapy of brain cancer.
@en
P2860
P1476
Intravenous, non-viral RNAi gene therapy of brain cancer.
@en
P2860
P304
P356
10.1517/14712598.4.7.1103
P407
P577
2004-07-01T00:00:00Z